The manufacturing process for B-domain deleted recombinant factor VIII.

Area of Science:

• Biotechnology
• Biopharmaceutical Manufacturing
• Hematology

Background:

• Hemophilia A treatment relies on factor VIII replacement therapy.
• Current therapies may carry risks of viral or microbial contamination.
• Development of safer, recombinant factor VIII is crucial.

Purpose of the Study:

• To describe the development of a cell bank for B-domain deleted recombinant coagulation factor VIII (BDDrFVIII).
• To outline the manufacturing process ensuring high purity and safety.
• To confirm BDDrFVIII as a consistent therapeutic option.

Main Methods:

• Stable insertion of the human BDDrFVIII gene into Chinese hamster ovary (CHO) cells.
• Selection of high-expressing cell lines and cell bank establishment.
• Multi-step purification including chromatography and viral inactivation.

Main Results:

• Consistent expression of active BDDrFVIII achieved through cell line selection.
• Purification process yielded a highly pure BDDrFVIII product.
• Final formulation free of human serum albumin, enhancing safety.

Conclusions:

• The developed cell bank supports routine manufacturing of BDDrFVIII.
• The manufacturing process ensures a safe and effective treatment for hemophilia A.
• BDDrFVIII represents a reliable and pure factor VIII concentrate.